È­¼øÀü³²´ëº´¿ø ±è¿µÃ¶ ±³¼ö, ´ëÇÑÆó¾ÏÇÐȸ¿ì¼ö³í¹®»ó ¼ö»ó

´º½ºÀÏÀÚ: 2010³â06¿ù29ÀÏ 00½Ã00ºÐ

È­¼øÀü³²´ëÇб³º´¿ø È£Èí±â³»°ú ±è¿µÃ¶ ±³¼ö°¡ Áö³­ 25ÀÏ °æÁÖ Çö´ëÈ£ÅÚ¿¡¼­ °³ÃÖµÈ ´ëÇÑÆó¾ÏÇÐȸ Ãá°èÇмú´ëȸ¿¡¼­‘Æó¾Ï »óÇǼ¼Æ÷ ¼ºÀåÀÎÀÚ ¼ö¿ëü(EGFR) À¯ÀüÀÚÀÇ T790M º¯ÀÌ¿¡ ÀÇÇÑ ¾àÁ¦ ³»¼ºÀ» ±Øº¹ÇÒ ¼ö ÀÖ´Â Erlotinib°ú Ç×¾ÏÈ­ÇоàÁ¦ÀÇ º´ÇÕ¹æ¹ý (Combining Erlotinib with Cytotoxic Chemotherapy May Overcome Resistance Caused by T790M Mutation of EGFR Gene in Non-Small Cell Lung Carcinoma)’¶ó´Â ÁÖÁ¦ÀÇ ³í¹® ¹ßÇ¥·Î ¿ì¼ö³í¹®¿¡ ¼±Á¤µÆ´Ù.

 


ÀÌ ´º½ºÅ¬¸®ÇÎÀº BKT´º½º{www.bktimes.net}¿¡¼­ ¹ßÃéµÈ ³»¿ëÀÔ´Ï´Ù.